Seedlings 2017 has now sold out, please email Darryl@buddingtech.com to be added to a wait list.

Gain an in-depth understanding of the political, economic and investment trends/opportunities within the medical cannabis industry

Ticket Sales Are Limited to 100!

Overview of event:

In collaboration with Spark Festival, medical cannabis accelerator BuddingTech is hosting Seedlings 2.0. Last year, Seedlings was launched as Australia's first medical cannabis industry event highlighting the key challenges and opportunities, and was met with resounding success.

Set to be worth more than $50 billion within the next 10 years, medical cannabis is unquestionably an emerging growth industry. Seedlings has been designed to raise awareness of the challenges and opportunities presented by medical cannabis to develop a responsible, innovative, and politically-engaged legal cannabis industry in Australia.

The event will present a series of speakers who will provide insight into the cannabis industry from a patient, political, technological, medical, and industry perspective.

There will also be a panel of industry experts and guests from the medical cannabis community.

Join us for an insightful evening where you will learn about the latest advancements in research and innovation, investment opportunities, and the emerging start-ups that are shaping this rapidly expanding sector.

Times and speakers:

6.00pm: Drinks + Networking

6:30pm: Ben Oakley - Patient advocate

6:45pm: Dr Ross Walker - MGC Pharma (Keynote)

7.00pm: Blaise Bratter - Medical Cannabis Council

7:15pm: Break for 15 minute break

7:30pm: Panel discussion

8:00pm: Panel Q&A session

8:30pm: Panel concludes and networking begins

9:00pm: Event concludes

*Please note that drinks and light refreshments will be provided.

Speakers:

Ben Oakley - The patient's perspective

Ben is a medical cannabis campaigner and activist. He has an incredible story about using cannabis oil to treat a rare condition that he suffers from known as, ‘stiff person syndrome’. Ben will share his harrowing experiences with conventional treatment options and why he is a devoted advocate for medical cannabis.

Dr Ross Walker - MGC Pharma

Dr Ross Walker is an eminent practicing cardiologist with a passion for people and health. Considered one of the world’s best keynote speakers and life coaches, he is the author of seven books (all of which have been best-sellers). Dr Walker is also a regular presenter on the Nine Network’s Today Show and A Current Affair and has most recently appeared as the medical expert on Excess Baggage. He also presents on radio stations 2UE, 6PR, 4BC and 3AW.

MGC Pharmaceuticals Limited (MGC), is a Perth based bio-pharmaceutical publically traded company with a focus on phytocannabinoid medications. The company has a research facility in Ljubljana, Slovenia, and is actively involved in research into phytocannabinoids and their potential for medical applications in both countries.

Capitalizing on years of experience in the innovative Israeli Medical Cannabis market, combined with exclusive strains of high CBD genetics and first to market advantages globally, MGC is creating a seamless, highly supervised supply chain, from planting to extraction, creating the highest quality resins, oils and proprietary delivery devices available in the market.

Blaise Bratter, General Manager - Medical Cannabis Council

The Medical Cannabis Council launched earlier this year and is proudly presenting Australia's first national not-for-profit body representing the medical cannabis industry.

Cancelled: Kevin Anderson MP - NSW Nationals Member for Tamworth

Elected in 2011, Keving Anderson has since been an advocate for medical cannabis in the NSW Parliament. When Lucy Haslam started campaigning for access to medical cannabis after her son, Dan, experience its positive effects when being treated with chemotherapy, Kevin was the first politician to listen. He pushed the NSW National Party, and the then Premier Mike Baird, to take up the fight.

Kevin is now working with his National Party colleagues on a new NSW Bill that will bring access to patients in need.

Panel:

We are currently putting together a list of notable medical cannabis industry leaders for our panel - Panel speakers include:

Michael Katz - Director at Ripple Capital

Michael Katz has worked in the academic sector for both the University of Sydney and UNSW, where his focus has been on developing and implementing social investment projects and internship programs within the business faculties, as well as managing action research projects. This includes initiating and managing the Medical Cannabis White Paper developed in collaboration with MGC Pharmaceuticals and Budding Tech.

Catherine Harvey - Chief Operations Officer of MMJ Phytotech

Ms. Catherine Harvey is a highly experienced pharmaceutical industry executive, with an extensive corporate background, having worked for multiple pharmaceutical organisations both domestically and overseas. She held executive leadership positions including Director of Business Development and Corporate Affairs at Mundipharma Pty Limited and Business Development Manager at Norwegian Pharmaceutical company, Nycomed.

Justin Sinclair - Research Fellow at NICM

Justin is a Research Fellow at NICM, an international leader in integrative medicine research based at Western Sydney University where he is also the co-ordinator of the Australian Medicinal Cannabis Research & Education Collaboration. For the last 2 years he has also served on United in Compassion’s Scientific Advisory Board, Australia’s leading medicinal cannabis patient advocacy group, in a pro bono capacity. His scientific background is in pharmacognosy (i.e. drugs that come from plants), but his research interests extend into botany, ethnopharmacology, analytical Phytochemistry, horticulture, and pathophysiology. He is currently a co-investigator on several clinical research projects in development around medicinal Cannabis and spends much of his time lecturing to medical practitioners, nurses, politicians and other allied health professionals about the therapeutic applications of the Cannabis genus. Justin has many years of industry experience in areas such as quality assurance, new product development and regulatory affairs involving herbal medicines and is a strong supporter of full spectrum plant extracts and understanding the deeper workings of the entourage effect.

Dr Teresa Nicoletti (Partner) - Mills Oakley

Dr Teresa Nicoletti leads Mills Oakley’s national IP, Health and Life Sciences team. Teresa is both a lawyer and scientist with more than 20 years’ experience in the pharmaceutical, biotechnology and medical device industries in Australia and New Zealand. She has also worked across a number of other product-related industries, including foods, cosmetics, veterinary pharmaceuticals, agrochemicals and industrial chemicals. More recently, a lot of her work has centered around the developing medicinal cannabis framework at both the Commonwealth and State/Territory levels.

Dr Andrew Beehag - Chief Executive Officer at Canndeo Ltd

Dr Andrew Beehag is CEO of Canndeo Ltd, a wholly owned subsidiary company of The Hydroponics Company Ltd (ASX:THC). Andrew is an experienced Senior Manager with 20 years’ experience working with large and small organisations in technology development and commercialisation. Andrew led the establishment of Canndeo in late 2016 as CEO of Agri Fibre Industries, an industrial hemp business and technology developer with more than 17 years’ experience in the growth of cannabis. Since establishment, Canndeo has grown rapidly to secure multiple Australian and international partnerships to build a medicinal cannabis business focused on leadership in both domestic production and importation leading medicinal cannabis formulations.Cameron McDonald-Stuart

Cameron McDonald-Stuart - Director at Medicabis

Cameron has been working in the cannabis industry for 5 years. Along the way he has been COO of Australia’s first medicinal cannabis licensee, gained Advanced Cannabis Extraction Certification, and is currently working on the ancillary cannabis-related sectors of Seed-to-Sale/Track ’n' Trace, AgTech and Education in Australia, the US and Canada.

Professor Iain McGregor - Academic Director at The Lambert Initiative

Iain McGregor is the Academic Director of the Lambert Initiative and an NHMRC Principal Research Fellow. He is responsible for academic and organisational leadership, strategic direction, governance and reporting, and the development and achievement of the preclinical and clinical research strategies. Iain oversees a team of more than 25 staff and students, including the Associate Directors, and reports to the Lambert Initiative Internal Management Group (IMG). Renowned in the field of medicinal cannabis research, Iain leads stakeholder relations, advocacy and education.